At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 45 enrolled
Drug / intervention
GRT-R910biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of a Self-Amplifying mRNA Prophylactic Vaccine Boost Against SARS-CoV-2 in Previously Vaccinated Healthy Adults 18 Years and Older
In Brief
A Phase 1 clinical trial evaluating GRT-R910 for COVID-19. Completed, enrolled 45 participants across 3 sites.
Detailed Summary
The primary objective was to assess the safety and tolerability of 2 different doses (10 or 30 µg) of GRT-R910 when administered as a boost in healthy adults previously vaccinated with the AstraZeneca, Janssen/Johnson and Johnson, Moderna, or Pfizer/BioNTech Coronavirus disease 2019 (COVID-19) vaccines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartSep 2021
First PostedDec 2021
Primary CompletionMay 2023
TodayJul 2026
First PostedDec 8, 2021
Enrollment StartSep 16, 2021
Primary CompletionMay 26, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 4.6 years ago
Interventions
GRT-R910biological
Injection administered intramuscularly